Precision Biosciences (DTIL) Income from Continuing Operations (2018 - 2026)
Precision Biosciences (DTIL) reported Income from Continuing Operations of 8387000.0 for Q1 2026, up 60.33% year-over-year from 5231019.82 in Q1 2025, and down 164.85% quarter-over-quarter from 12933000.0 in Q4 2025.
Precision Biosciences (DTIL) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has 9 years of Income from Continuing Operations data on file, last reported at 8387000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 8387000.0, up 60.33% year-over-year; the trailing twelve-month figure through Mar 2026 was 36575000.0 (up 6.76% YoY), and the FY2025 annual result was 49331000.0, down 132.9% from the prior year.
- Income from Continuing Operations fell to 8387000.0 in Q1 2026 per DTIL's latest filing, from 12933000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 25429000.0 in Q2 2024 and troughed at 29540000.0 in Q2 2022.
- A 5-year average of 11675941.18 and a median of 13642000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 1564.8% in 2024, then tumbled 582.47% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 10658000.0 in 2022, then slipped by 28.0% to 13642000.0 in 2023, then slumped by 74.05% to 23744000.0 in 2024, then soared by 154.47% to 12933000.0 in 2025, then plunged by 164.85% to 8387000.0 in 2026.
- Business Quant data shows DTIL's Income from Continuing Operations at 8387000.0 in Q1 2026, 12933000.0 in Q4 2025, and 20002000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Precision Biosciences | 168.99 Mn | 67.81 Mn | - | -8.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.39 Mn |
| Dec 31, 2025 | 12.93 Mn |
| Sep 30, 2025 | -20.00 Mn |
| Jun 30, 2025 | -21.12 Mn |
| Mar 31, 2025 | -21.14 Mn |
| Dec 31, 2024 | -23.74 Mn |
| Sep 30, 2024 | -19.77 Mn |
| Jun 30, 2024 | 25.43 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -13.64 Mn |
| Sep 30, 2023 | -11.07 Mn |
| Jun 30, 2023 | -1.74 Mn |
| Mar 31, 2023 | -11.83 Mn |
| Dec 31, 2022 | -10.66 Mn |
| Sep 30, 2022 | -13.91 Mn |
| Jun 30, 2022 | -29.54 Mn |
| Mar 31, 2022 | -27.21 Mn |
| Dec 31, 2021 | -30.71 Mn |
| Sep 30, 2021 | -11.55 Mn |
| Jun 30, 2021 | 21.66 Mn |